Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

Inclusion Criteria Patients must have: * HIV antibody positive. * CD4 cell counts less than 500/mm3. * Adequate general health. * No significant deterioration in performance status within the past month. * Prior treatment with a stable regimen of antiretroviral medication for at least 4 weeks prior to study. Prior Medication: Required: * Stable regimen of antiretroviral medication for at least 4 weeks prior to study entry. Allowed: * Aerosolized pentamidine for PCP prophylaxis. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Intercurrent infection. * Clinically significant abnormality on EKG. * Known hypersensitivity to quinolines. * Known hemoglobin M abnormality. * Known NADH methemoglobin reductase deficiency. * Positive test for G6PD deficiency. * Fever. Prior Medication: Excluded: * Other systemic medication (other than AZT, ddC, ddI, methadone, acyclovir, and NSAIDs) within 3 days prior to study entry.